Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo ...

As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline.  | As obesity ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...

Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held ...

One of the more interesting moves that came this quarter was from the Duquesne Family Office, led by billionaire investor ...

Novo Nordisk (NVO) will be forced to lower employee bonuses in its home country, Denmark, as the company doubles down on a ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Novo Nordisk's (NVO) challenges and higher U.S. tariffs are cited as Denmark cuts 2025 growth forecast to 1.4%. Read more here.